$CPBBullishMed

Benzinga

U.S. stocks rose Monday: the Dow was up 0.33% to 51,035.65, the Nasdaq gained 0.84% to 25,924.27, and the S&P 500 rose 0.59% to 7,427.45. Energy shares climbed 2.2%, while communication services fell 1.2%. Campbell’s (CPB) reported Q3 adjusted EPS of 50 cents vs 48 cents expected, with sales of $2.366B vs $2.381B. Oil rose to $90.99; gold fell to $4,352.00.

7/10
8/10
Med
Bullish
reported Monday (during the trading session)
risk-on tone with broader indices higher; CPB-specific catalyst is earnings beat

Earnings beat with modest sales miss suggests margin/earnings resilience but potential caution on top-line momentum.

Campbell’s posted Q3 adjusted EPS of 50 cents, beating estimates, while sales missed slightly versus expectations.

Near-term upside bias possible on the EPS beat, tempered by the sales shortfall.

Background

This is a daily market wrap that highlights Campbell’s Q3 earnings as the top company headline.

Why it matters

CPB’s earnings beat is the only company-specific fundamental catalyst in the text; broader market direction is supportive but not CPB-specific.

Market relevance

CPB is the sole named US-listed company with a fresh earnings datapoint, offering a tradable catalyst for the session.

Market effects

Energy strength (+2.2%) and mixed communication services (-1.2%) frame a rotation backdrop for consumer staples like CPB.

Eurozone and Asia were mixed/lower, but US indices were up, limiting cross-region spillover risk.

Oil up and gold down can influence inflation expectations and consumer demand sentiment, indirectly affecting staples.

Alternative perspectives

The sales miss ($2.366B vs $2.381B) could outweigh the EPS beat if investors focus on demand/volume rather than cost discipline.

No guidance, margin detail, or segment breakdown is provided; traders may need follow-up disclosures to judge whether the EPS beat is sustainable.

Key entities

  • Campbell’s Company

    Reported Q3 adjusted EPS of 50 cents vs 48 cents estimate; sales $2.366B vs $2.381B expectation.

Related articles

$CPBMedAI 8/10

Campbells’ Out with Q3 Figures

Campbell’s (NASDAQ:CPB) reported Q3 FY2026 results for the quarter ended May 3. Net sales fell 4% to $2.4B; organic sales also down 4% on lower volume/mix, offset by net price gains. Gross profit dropped 11% to $650M and margin to 27.5%. Adjusted EBIT fell 24% to $274M. CEO said results were in line but under pressure.

$CPBMed

Benzinga

Campbell’s (CPB) discussed its Q3 results on an earnings call, citing potential fiscal 2027 inflation pressures of 5–6% tied to higher oil prices. The company plans to offset via productivity and cost actions, including a $100 million SGA reduction and an early retirement package, while aiming to stabilize earnings and reduce leverage. Campbell’s said it has no near-term dividend increase plans, is considering hybrid debt to support its credit rating, and is reviewing its snacks portfolio to foc

$CPBMed

Benzinga

Campbell’s (NASDAQ:CPB) will report Q3 earnings before the open on Monday, June 8, according to Benzinga. Analysts expect EPS of 48 cents, down from 73 cents a year earlier, and revenue of $2.38 billion versus $2.48 billion last year, per Benzinga Pro. The company also declared a 39-cent quarterly dividend on May 13.

$CHWYLow

3 Absurdly Cheap Stocks to Buy With $1,000 While the Market Is This Nervous

The article argues investors may find consumer-stock bargains despite market nervousness. It highlights Chewy (CHWY) after fiscal 2025 net sales rose 6% and free cash flow rose 24% to $562 million; Target (TGT) after CEO Michael Fiddelke pledged $5 billion and Q1 fiscal 2026 net sales rose 7%; and Campbell’s (CPB) amid a 5% YoY Q2 fiscal 2026 sales decline but trading at 11x earnings and a ~7.4% dividend yield.

$DELLMedAI 8/10

Microsoft initiated, Dell upgraded: Wall Street's top analyst calls

Morgan Stanley upgraded Dell to Equal Weight from Underweight and set a $448 target (from $170), citing Dell’s Q1 results and a Taiwan visit as signs it’s managing the semiconductor supply shortage better than peers. Other moves: Guggenheim raised Zscaler to Buy ($214); Citi to Buy Kohl’s ($22); Wells Fargo to Overweight Tandem Diabetes ($27); Truist to Outperform Federal Realty ($130). Truist cut Accenture to Hold ($210); Stephens cut Campbell’s to Equal Weight ($21). Texas Capital cut Caesars